title: [Time-influencing factors for biochemical progression following radical prostatectomy].
abstract: BACKGROUND
  We assessed the time-influencing clinical-pathological factors for biochemical progression of an equal series of patients from a single institution.
  
  
  METHODS
  Retrospective analysis of 278 patients with biochemical progression following prostatectomy. We considered biochemical progression to be PSA>0.4 ng/ml. We performed the trial using the Cox model (univariate and multivariate) and using the Student's t-test to compare averages.
  
  
  RESULTS
  With a mean follow-up of 4 (±3 DE) years, the univariate study showed a mean until progression for the Gleason score 2-6 in the biopsy of 824 days and 543 for the Gleason score 7-10 (p=0.003). For negative surgical margins, the mean was 920 days and 545 for positive margins (p=0.0001). In the case of a Gleason score 2-7 in the specimen, the mean was 806 days and 501 for a Gleason score 8-10 (p=0.001). Lastly, the mean for the cases with Ki-67 negative in the specimen (< 10%) was 649 days and 345 for Ki-67 positive (> 10%) (p=0.003). In the multivariate study, Ki-67 (OR 1.028; IC 95% 1-1.01; p=0.0001) and Gleason score 8-10 (OR 1.62; IC 95% 1.5-2.45; p=0.026) in the specimen, and initial PSA >10 ng/ml (OR 1.02; IC 95% 1.01-1.04; p=0.0001) were independent variables. Using these variables, we designed a predictive model with three groups. The time until the progression of each group was 1,081, 551 and 218 days respectively.
  
  
  CONCLUSIONS
  The Gleason score 7-10 in the prostate biopsy, the presence of Ki-67, the positive margins and the Gleason score 8-10 in the specimen, and the initial PSA > 10 ng/ml are time-influencing factors until biochemical progression. Pathological Gleason score 8-10, PSA > 10 ng/ml and Ki-67 are independent factors.
authors.affiliation: Departamento de Urología, Clínica Universidad de Navarra, España. javiferbar@hotmail.com
authors.forename: J
authors.initials: J
authors.lastname: Barba
authors.forename: X
authors.initials: X
authors.lastname: Brugarolas
authors.forename: E
authors.initials: E
authors.lastname: Tolosa
authors.forename: A
authors.initials: A
authors.lastname: Rincón
authors.forename: L
authors.initials: L
authors.lastname: Romero
authors.forename: D
authors.initials: D
authors.lastname: Rosell
authors.forename: J E
authors.initials: JE
authors.lastname: Robles
authors.forename: J J
authors.initials: JJ
authors.lastname: Zudaire
authors.forename: J M
authors.initials: JM
authors.lastname: Berian
authors.forename: J I
authors.initials: JI
authors.lastname: Pascual
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000556:secondary* / Q000601:surgery; D001706:Biopsy; D018450:Disease Progression; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors
chemical_list: D017430:Prostate-Specific Antigen